WT1 and leukemia: In cooperation with Takara Bio Inc. and Mie University, we have originally developed the siTCR vector system, and recently launched a clinical trial using a therapeutic siTCR vector targeting a leukemia antigen, Wilms Tumor 1 (WT1-siTCR vector) [39], for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) (UMIN 00001159).